Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Adaptive Treatment for Cocaine Dependence

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
University of Pennsylvania
ClinicalTrials.gov Identifier:
NCT01032135
First received: December 14, 2009
Last updated: January 4, 2016
Last verified: January 2016

December 14, 2009
January 4, 2016
October 2008
December 2013   (final data collection date for primary outcome measure)
Determine the relative effectiveness of MI-IOP and MI-PC in the full study sample with regard to treatment engagement over weeks 1-12 and cocaine use over weeks 1-24. [ Time Frame: engagment measured to week 12, cocaine use measured to week 24 ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01032135 on ClinicalTrials.gov Archive Site
Determine whether the relative effectiveness of MI-IOP and MI-PC varies as a function of engagement group, with regard to treatment engagement over weeks 1-12 and cocaine use outcomes over weeks 1-24. [ Time Frame: Engagement measured until week 12, cocaine use measured until week 24. ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Adaptive Treatment for Cocaine Dependence
Adaptive Treatment for Cocaine Dependence
  1. Primary objective #1: Determine the relative effectiveness of MI-IOP and MI-PC in the full study sample with regard to treatment engagement over weeks 1-12 and cocaine use over weeks 1-24.

    • Hypothesis 1: An intervention that explores several possible treatment options with the patient and provides the chosen option (e.g., MI-PC) will produce higher rates of treatment engagement than an intervention focused on engagement in IOP only (e.g., MI-IOP).
    • Hypothesis 2: An intervention that explores several possible treatment options with the patient and provides the chosen option (e.g., MI-PC) will produce better cocaine use outcomes than an intervention focused on engagement in IOP only (MI-IOP).
    • Secondary analysis 1: Among the Non-engaged patients, determine rates of selection of each of the three options in MI-PC, retention rates within each option, and cocaine use outcomes in each option.
    • Secondary analysis 2: Among the Engaged patients, determine rates of selection of each of the three options in MI-PC, retention rates within each option, and cocaine use outcomes in each option.
  2. Primary objective #2: Determine whether the relative effectiveness of MI-IOP and MI-PC varies as a function of engagement group, with regard to treatment engagement over weeks 1-12 and cocaine use outcomes over weeks 1-24.

    • Hypothesis 1: The predicted main effect on retention favoring MI-PC over MI-IOP will be significantly larger among patients in the Non-engaged group than among those in the Engaged group.
    • Hypothesis 2: The predicted main effect on cocaine use outcomes favoring MI-PC over MI-IOP will be significantly larger among patients in the Non-engaged group than among those in the Engaged group.

3. Secondary objective #1: Examine outcomes on three secondary measures: percent days abstinent from all substances, negative consequences of drug use, and HIV high risk behaviors.

  • Hypothesis 1: Outcomes on the secondary measures will be better in MI-PC than in MI-IOP.

    4. Secondary objective #2: Test hypotheses concerning potential mediators of the predicted main effect favoring MI-PC over MI-IOP.

  • Hypothesis 1: The predicted advantage of MI-PC over MI-IOP will be mediated by greater increases in motivation, self-efficacy, commitment to abstinence, and self-help involvement in MI-PC.

    5. Secondary objective #3: Test hypotheses concerning effect of additional MI intervention after initial non-engagement persists through 12 weeks.

  • Hypothesis 1: A second telephone MI intervention will produce higher rates of subsequent engagement and less cocaine use than no further MI.
Interventional
Phase 2
Phase 3
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Cocaine Dependence
  • Behavioral: Motivational Interviewing
    2 sessions at week 2, potential 2 sessions at week 8 if the participant drops out.
    Other Name: MI
  • Behavioral: Telephone counseling
    one telephone counseling session per week for 10 weeks.
    Other Name: Telephone based stepped care.
  • Behavioral: Cognitive Behavioral Therapy (CBT) Counseling
    One CBT session per week, for 10 weeks.
    Other Name: CBT
  • Drug: medication management
    Prescription for naltrexone
    Other Name: MM
  • Behavioral: Intensive OutPatient Therapy
    Return to IOP, group therapy 3 times weekly for about three hours a day.
    Other Name: IOP
  • 1-MI-IOP Engaged
    Randomized to treatment as usual, and they attend regularly.
    Intervention: Behavioral: Motivational Interviewing
  • Experimental: 2-MI-IOP Non-Engaged
    Randomized to treatment as usual, and do not attend.
    Interventions:
    • Behavioral: Motivational Interviewing
    • Behavioral: Telephone counseling
    • Behavioral: Cognitive Behavioral Therapy (CBT) Counseling
    • Drug: medication management
    • Behavioral: Intensive OutPatient Therapy
  • 3-MI-PC Engaged
    Randomized to treatment choice, but remain attending treatment as usual.
    Interventions:
    • Behavioral: Motivational Interviewing
    • Behavioral: Telephone counseling
    • Behavioral: Cognitive Behavioral Therapy (CBT) Counseling
  • Experimental: 4-MI-PC
    Randomized to treatment choice, and do not attend treatment as usual, so the choice option is used.
    Interventions:
    • Behavioral: Motivational Interviewing
    • Behavioral: Telephone counseling
    • Behavioral: Cognitive Behavioral Therapy (CBT) Counseling
    • Drug: medication management
    • Behavioral: Intensive OutPatient Therapy
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
300
December 2013
December 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. meet DSM-IV criteria for lifetime cocaine dependence and have used cocaine in the prior 6 months;
  2. be > 18 years of age;
  3. be judged clinically appropriate for IOP (e.g., no current psychotic disorder or evidence of severe dementia, and no acute medical problem requiring inpatient treatment;
  4. have no regular IV heroin use during the past year;
  5. have access to a telephone;
  6. be willing to be randomized and participate in research; and
  7. no current participation in methadone or other forms of DA treatment, other than IOP. Finally, because of study follow-up requirements, subjects will
  8. be required to be metropolitan area residents, and
  9. be able to provide the name, verified telephone number, and address of at least two contacts who can provide locator information on the patient during follow-up. We will include patients with dependence on other substances, provided that they are cocaine dependent and meet other inclusion criteria.

Exclusion Criteria:

  1. have a current psychotic disorder (as assessed with the psychotic screen from the MINI) or evidence of dementia severe enough to prevent participation in outpatient treatment;
  2. have acute medical problem requiring immediate inpatient treatment; or
  3. are currently participating in methadone or other forms of DA treatment, other than IOP.
Female
18 Years to 75 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01032135
807092, IND: 101,486
No
Not Provided
Not Provided
University of Pennsylvania
University of Pennsylvania
Not Provided
Principal Investigator: James R. McKay, Ph.D University of Pennsylvania
University of Pennsylvania
January 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP